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Background
Left ventricular assist devices are increasingly used as
bridges to transplantation. Malignant tumors can be dis-
covered on the pre-implantation or pre-transplantation
screening and surgeons may be required to perform
tumors resection in those patients. We reported our
experience on this challenge given the hemodynamic,
hematologic and outcome considerations.
Methods
34 patients underwent implantation of Heartmate II
(HMII); we performed 4 resections of malignant tumors:
2 partial nephrectomies for renal tumors (8 months
after implantation), a left segmentectomy for lung can-
cer (2 years later) under videothoracoscopy and a
tumorectomy with lymphadenectomy for breast cancer
(9 months later). Renal tumors were diagnosed during
the pre-implantation screening; while the others were
diagnosed after the device’s implantation.
Results
Invasive surgical approach can be difficult in patients
with heart failure; therefore we decided to support them
with HMII before the renal tumor’s resection. Surgery
in patients supported with HMII device expose to bleed-
ing as well as hemostasis revealed an acquired Von
Willebrand disease in 2 patients. 5 days prior to the sur-
gery, we substituted Vitamin K antagonist with heparin
(PTT1,5- 2). None of them experienced bleeding. Dur-
ing surgery, the use of the right lateral decubitus in 3
patients resulted in decreased cardiac output, which was
resolved with vasopressor, hydration and decrease of the
pump speed. Length of stay in intensive care unit was
1-4 days and reoperation was necessary for evacuation
of post nephrectomy hematoma. After discussion with
cardiologists and oncologists, 1 patient received heart
transplant 2 years after partial nephrectomy and com-
plete remission;3 are on the waiting list.
Conclusion
Our results suggest that, in the setting of cancer in a
pretransplant candidate, tumors resection can be safely
achieved even for high-risk HMII patients and regaining
candidacy for heart transplant is conceivable.
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